New concepts of the pathogenesis of alcoholic liver disease lead to novel treatments

Current Gastroenterology Reports

Volumn 6, Issue 1, 2004, Pages 60-65

  Lieber, Charles S ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; COLCHICINE; CORTICOSTEROID; CYTOCHROME P450 2E1; MEDIUM CHAIN TRIACYLGLYCEROL; METHIONINE; PENTOXIFYLLINE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE METHYLTRANSFERASE; PHOSPHOLIPID; POLYENE PHOSPHATIDYLCHOLINE; PREDNISOLONE; S ADENOSYLMETHIONINE; SILYMARIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIOXIDANT; CYTOKINE;

ALCOHOL CONSUMPTION; ALCOHOL LIVER DISEASE; CLINICAL TRIAL; CYTOKINE RELEASE; ENZYME ACTIVATION; HUMAN; KUPFFER CELL; LIPID PEROXIDATION; NONHUMAN; OXIDATIVE STRESS; REVIEW; ALCOHOLISM; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; FEMALE; HOSPITALIZATION; LIVER FUNCTION TEST; MALE; METABOLISM; PATHOPHYSIOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ALCOHOLISM; ANTIOXIDANTS; COLCHICINE; CYTOKINES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LIPID PEROXIDATION; LIVER DISEASES, ALCOHOLIC; LIVER FUNCTION TESTS; MALE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; S-ADENOSYLMETHIONINE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 1442282934     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-004-0027-0     Document Type: Review

References (55)

1. Raynard B, Balian A, Fallik D, et al.: Risk factors of fibrosis in alcohol-induced liver disease. Hepatology 2002, 35:635-638.
2. Anton RF, Lieber CS, Tabakoff B: Carbohydrate-deficient transferrin and gamma-glutamyltransferase for the detection and monitoring of alcohol use: results from a multisite study. Alcohol Clin Exp Res 2002, 26:1215-1222.
3. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP: Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992, 49:876-880.
4. Lieber CS: Alcoholic liver disease: new insights in pathogenesis lead to new treatments. J Hepatology 2000, 32:113-128.
5. Duce AM, Ortiz P, Cabrero C, Mato JM: S-adenosyl-L-methionine synthetase and phospholipid methyltransferase are inhibited in human cirrhosis. Hepatology 1988, 8:65-68.
6. Lieber CS: Alcoholic liver injury: pathogenesis and therapy in 2001. Pathol Biol 2001, 49:738-752.
7. Lieber CS, Casini A, DeCarli LM, et al.: S-adenosyl-L-methionine attenuates alcohol-induced liver injury in the baboon. Hepatology 1990, 11:165-172.
8. Frezza M, Surrenti C, Manzillo G, et al.: Oral S-adenosylmethionine in the symptomatic treatment of intrahepatic cholestasis: a double-blind placebo controlled study. Gastroenterology 1990, 99:211-215.
9. Vendemiale G, Altomare E, Trizio T, et al.: Effect of oral S-adenosyl-L-methionine on hepatic glutathione in patients with liver disease. Scand J Gastroenterol 1989, 24:407-415.
10. Mato JM, Cámara J, Fernández de Paz J, et al.: S-Adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicentre clinical trial. J Hepatology 1999, 30:1081-1089.
11. Lieber CS: Medical and Nutritional Complications of Alcoholism: Mechanisms and Management. New York: Plenum Press; 1992.
12. Moshage H, Casini A, Lieber CS: Acetaldehyde selectively stimulates collagen production in cultured rat liver fat-storing cells but not in hepatocytes. Hepatology 1990, 12:511-518.
13. Ma X, Svegliati-Baroni G, Poniachik J, et al.: Collagen synthesis by liver stellate cells is released from its normal feedback regulation by acetaldehyde-induced modification of the carboxyl-terminal propeptide of procollagen. Alcohol Clin Exp Res 1997, 21:1204-1211.
14. Savolainen E-R, Leo MA, Timpl R, Lieber CS: Acetaldehyde and lactate stimulate collagen synthesis of cultured baboon liver myofibroblasts. Gastroenterology 1984, 87:777-787.
15. Casini A, Cunningham M, Rojkind M, Lieber CS: Acetaidehyde increases procollagen type I and fibronectin gene transcription in cultured rat fat-storing cells through a protein synthesis-dependent mechanism. Hepatology 1991, 13:758-765.
16. Lieber CS: Cytochrome P4502E1: its physiological and pathological role. Physiol Rev 1997, 77:517-544.
17. Lieber CS: Prevention and treatment of liver fibrosis based on pathogenesis. Alcohol Clin Exp Res 1999, 23:944-949.
18. Lieber CS, Robins SJ, Li J, et al.: Phosphatidylcholine protects against fibrosis and cirrhosis in the baboon. Gastroenterology 1994, 106:152-159.
19. Mak KM, Leo MA, Lieber CS: Alcoholic liver injury in baboons: transformation of lipocytes to transitional cells. Gastroenterology 1984, 87:188-200.
20. Mak KI, Lieber CS: Lipocytes and transitional cells in alcoholic liver disease: a morphometric study. Hepatology 1988, 8:1027-1033.
21. Poniachik J, Baraona E, Zhao J, Lieber CS: Dilinoleoylphosphatidylcholine decreases hepatic stellate cell activation. J Lab Clin Med 1999, 133:342-348.
22. Arai M, Gordon ER, Lieber CS: Decreased cytochrome oxidase activity in hepatic mitochondria after chronic ethanol consumption and the possible role of decreased cytochrome aa3 content and changes in phospholipids. Biochim Biophys Acta 1984, 797:320-327.
23. Navder K, Baraona E, Lieber CS: Polyenylphosphatidylcholine attenuates alcohol-induced fatty liver and hyperlipemia in rats. J Nutr 1997, 127:1800-1806.
24. Lieber CS, Leo MA, Aleynik SI, et al.: Polyenylphosphatidylcholine decreases alcohol-induced oxidative stress in the baboon. Alcohol Clin Exp Res 1997, 21:375-379.
25. Ma X, Zhao J, Lieber CS: Polyenylphosphatidylcholine attenuates non-alcoholic hepatic fibrosis and accelerates its regression. J Hepatology 1996, 24:604-613.
26. Li J-J, Yim C-I, Leo MA, et al.: Polyunsaturated lecithin prevents acetaldehyde-mediated hepatic collagen accumulation by stimulating collagenase activity in cultured lipocytes. Hepatology 1992, 15:373-381.
27. Lieber CS, Robins SJ, Leo MA: Hepatic phosphatidylethanolamine methyltransferase activity is decreased by ethanol and increased by phosphatidylcholine. Alcohol Clin Exp Res 1994, 18:592-595.
28. Bird GLA, Panos MZ, Polson R, et al.: Activity of polyunsaturated phosphatidylcholine in HbsAg negative chronic active hepatitis and acute alcoholic hepatitis. Z Gastroenterol 1991, 29:21-24.
29. Niederau C, Strohmeyer G, Heinges T, et al.: Polyunsaturated phosphatidyl-choline and interferon alpha for treatment of chronic hepatitis B and C: a multi-center, randomized, double blind, placebo-controlled trial. Hepatogastroenterology 1998, 45:797-804.
30. Lieber CS, Leo MA, Aleynik SI, et al.: Increasing circulating level of dilinoleoylphosphatidylcholine is associated with protection against alcohol induced oxidative stress and liver fibrosis in man [abstract]. Hepatology 2000, 32:386A.
31. Lieber CS, Weiss DG, Groszmann R, et al.: VA Cooperative study of polyenylphosphatidylcholine in alcoholic liver disease: effects on drinking behavior by nurse/physician teams. Alcohol Clin Exp Res 2003, 27:1757-1764.
32. Lieber CS, Weiss DG, Groszmann R, et al.: Cooperative study of polyenylphosphatidylcholine in alcoholic liver disease. Alcohol Clin Exp Res 2003, 27:1765-1772.
33. Ferenci P, Dragosics B, Dittrich H, et al.: Randomized controlled trial of silymarin-treatment in patients with cirrhosis of the liver. J Hepatology 1989, 9:105-113.
34. Pares A, Planas R, Torres M, et al.: Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. J Hepatology 1998, 28:615-621.
35. Lieber CS, Leo MA, Cao Q, et al.: Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons. J Clin Gastroenterol 2003, 37:336-339.
36. Leo MA, Rosman A, Lieber CS: Differential depletion of carotenoids and tocopherol in liver diseases. Hepatology 1993, 17:977-986.
37. de la Maza MP, Petermann M, Bunout D, Hirsch S: Effects of long-term vitamin E supplementation in alcoholic cirrhotics. J Am Coll Nutr 1995, 15:192-196.
38. Lieber CS, Lefevre A, Spritz N, et al.: Difference in hepatic metabolism of long and medium-chain fatty acids: the role of fatty acid chain length in the production of the alcoholic fatty liver. J Clin Invest 1967, 46:1451-1460.
39. Nanji AA, Yang EK, Fogt F, et al.: Medium chain triglycerides and vitamin E reduced the severity of established experimental alcoholic liver disease. J Pharmacol Exp Ther 1996, 277:1694-1700.
40. Cabre E, Rodriguez-Iglesias P, Caballeria J, et al.: Short-and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial. Hepatology 2000, 32:36-42.
41. Khoruts A; Stahnke L, McClain CJ, et al.: Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients. Hepatology 1991, 13:267-276.
42. Sheron N, Bird G, Goka J, et al.: Elevated plasma interleukin-6 and increased severity and mortality in alcoholic hepatitis. Clin Exp Immunology 1991, 84:449-453.
43. Koivisto T, Mishin V, Mak KM, et al.: Induction of cytochrome P-4502E1 by ethanol in rat Kupffer cells. Alcohol Clin Exp Res 1996, 20:207-212.
44. Batey R, Cao Q, Madsen G, et al.: Decreased tumor necrosis factor-alpha and interleukin-1alpha production from intra-hepatic mononuclear cells in chronic ethanol consumption and up regulation by endotoxin. Alcohol Clin Exp Res 1998, 22:150-156.
45. Akriviadis E, Botla R, Briggs W, et al.: Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind survival in controlled trial. Gastroenterology 2000, 119:1637-1648.
46. Jalan R, Williams R, Kaser R: Clinical and cytokine responses to anti-TNF antibody therapy in severe alcoholic hepatitis [abstract]. Hepatology 2001, 34:441A.
47. Oneta CM, Mak KM, Lieber CS: Dilinoleoylphosphatidylcholine selectively modulates lipopolysaccharide-induced Kupffer cell activation. J Lab Clin Med 1999, 134:466-470.
48. Kato J, Sato Y, Inui N, et al.: Ethanol induces transforming growth factor-alpha expression in hepatocytes, leading to stimulation of collagen synthesis by hepatic stellate cells. Alcohol Clin Exp Res 2003, 27:58S-63S.
49. Cao Q, Mak KM, Lieber CS: DLPC decreases TGF-beta1-induced collagen mRNA by inhibiting p38 MAPK in hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2002, 283:G1051-G1061.
50. Carithers; RL Jr, Herlong FH, Diehl AM, et al.: Methylprednisone therapy in patients with severe alcoholic hepatitis: a randomized multicenter trial. Ann Intern Med 1989, 110:685-690.
51. Ramond MJ, Poynard T, Rueff B: A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med 1992, 326:507-512.
52. Christensen E, Gluud C: Glucocorticoids are effective in alcoholic hepatitis: a meta-analysis adjusting for confounding variables. Gut 1995, 37:113-118.
53. Kershenobich D, Vargas F, Garcia-Tsao G, et al.: Colchicine in the treatment of cirrhosis of the liver. N Engl J Med 1988, 318:1709-1713.
54. Morgan T, Nemchausky B, Schiff E, et al.: Colchicine does not prolong life in patients with advanced alcoholic cirrhosis: results of a prospective, randomized, placebo-controlled, multicenter VA trial (CSP 352) [abstract]. Gastroenterology 2002, 122:A342.
55. Aleynik MK, Lieber CS: Dilinoleoylphosphatidylcholine decreases ethanol-induced cytochrome P4502E1. Biochem Biophys Res Commun 2001, 288:1047-1051.